Effect of Sustained-Release Verapamil on the Morning Systemic Arterial Pressure Surge During Daily Activity in Patients With Systemic Hypertension

• Published in: The American journal of cardiology Vol. 79; no. 9; pp. 1252 - 1255
• Main Authors: Rosito, MD, Guido A, Gebara, MD, Otavio C.E, McKenna, RN, Carol A, Solomon, MD, Harold S, Muller, MD, James E, Tofler, MD, Geoffrey H
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.05.1997; Elsevier; Elsevier Limited
• Subjects: Adult; Analysis of Variance; Antihypertensive agents; Biological and medical sciences; Blood pressure; Blood Pressure - drug effects; Blood Pressure - physiology; Cardiovascular system; Circadian Rhythm - drug effects; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Drug therapy; Female; Fourier Analysis; Heart Rate - drug effects; Humans; Hypertension; Hypertension - drug therapy; Hypertension - physiopathology; Male; Medical sciences; Middle Aged; Monitoring, Physiologic; Pharmacology. Drug treatments; Verapamil - administration & dosage; Human; Hypertension; Night; Controlled release form; Treatment efficiency; Calcium antagonist; Morning; Variations; Cardiovascular disease; Chemotherapy; Treatment; Aralkylamine; Antihypertensive agent; Arterial pressure; Verapamil
• ISSN: 0002-9149; 1879-1913
• DOI: 10.1016/S0002-9149(97)00093-3

In a placebo-controlled study of 13 subjects with systemic hypertension, sustained-release verapamil reduced the morning surge in systolic pressure by 10.2 mm Hg (p = 0.04), diastolic pressure by 11.1 mm Hg (p = 0.008), and heart rate by 3.3 beats/min (p = 0.17). Blunting of the morning hemodynamic surge may be a mechanism by which verapamil could reduce the risk of plaque disruption and acute coronary events in the morning.